Entering text into the input field will update the search result below

#16: Pharma/Healthcare Daily Take

Aug. 11, 2015 1:02 AM ETSHPHF, MCRPF
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Essex Bio-Technology (1061.HK - HK$4.74) releases a strong set of interim results. Revenue was up 35.5% YoY to HK$313mn and profit rose 68.8% YoY to HK$52mn. In terms of business segment, sales of surgical products and ophthalmic products were up 49.2% YoY and 22.5% YoY to HK$124.4mn and HK$171.3mn respectively. The overall GPM for Beifuji and Beifushu series maintained at 90.9%, and the blended GPM was down mildly by 0.2ppt YoY to 81.9%. Equity settled share-based payments were HK$2.9mn (1H14: HK$6.3mn). No interim dividend (1H14: nil). Net cash position maintained (HK$74.1mn cash vs. HK$31.6mn bank borrowings). Moreover, the company said it is developing a new VEGF nano-antibody and are investigating the potential of antibody as a future treatment for cancer and age-related macular degeneration. At $4.72, Essex Bio-Technology is trading at 27.4x TTM earnings.

Phoenix Healthcare (1515.HK - HK$12.78) announced interim results for the six months ended 30 June. Revenue was up 18.8% YoY to RMB602mn, mainly driven by its supply chain business. Net profit rose 23.4% YoY to RMB102mn. No interim dividend (1H14: nil). Share price closed at $12.78, up 0.8% yesterday.

Sihuan Pharmaceutical (460.HK - Suspended) released a voluntary announcement as the CFDA granted full approval of Phase I/II/III clinical trials for Pirotinib, an internally developed innovative patented oncology drug. The company expects clinical trial for Pirotinib to initiate first-in-patient in China in October 2015 as planned.

MicroPort (853.HK - HK$3.18) announced a voluntary recall of its Long 8 Varus Cobalt Modular Neck, as the company received 28 reports of implant fractures related to the recalled part (representing a 0.0286% rate of fracture). There are 784 units of the recalled part that are subject to this recall.

More on: https://onwritingpharma.wordpress.com/

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You